HLX51 study for advanced cancers: safety and early benefit
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial tests HLX51, a new anti-cancer medicine, to see if it is safe and tolerable in people with advanced solid tumors or lymphoma. It also studies how the body absorbs and processes the drug, and it may help if standard treatments didn’t work or aren’t possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old and can understand the study and sign consent.
- You have advanced solid cancer or lymphoma that can’t be treated with standard options.
- A doctor can measure at least one tumor spot on scans (measurable lesion).
- Your overall health is good enough (ECOG 0–1) and you’re expected to live more than 3 months.
- Your blood counts, liver tests, and kidney tests meet specific safety cutoffs.
- You must be able to follow timing rules for prior treatments (often 14–28 days depending on what you had).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug (HLX48) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
This trial tests a new experimental drug called HLX316 in people with advanced or metastatic (spread) solid cancers that have not responded to standard treatments. The drug is designed to help your immune system fight cancer cells.
This early-phase study tests a new drug called HLX37 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and how it works in the body.
This trial tests a new drug, HLX3901, for people with advanced small cell lung cancer or neuroendocrine cancer that has worsened after previous treatments. The goal is to see if it's safe and how the body handles it.
Hear when a new Solid Tumor, Adult Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.